Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Dynamic treatment regimens in small n, sequential, multiple assignment, randomized trials: An application in focal segmental glomerulosclerosis.

Chao YC, Trachtman H, Gipson DS, Spino C, Braun TM, Kidwell KM.

Contemp Clin Trials. 2020 Mar 19;92:105989. doi: 10.1016/j.cct.2020.105989. [Epub ahead of print]

PMID:
32200006
2.

A longitudinal examination of parent-reported emotional-behavioral functioning of children with mild to moderate chronic kidney disease.

Johnson RJ, Gerson AC, Harshman LA, Matheson MB, Shinnar S, Lande MB, Kogon A, Gipson DS, Warady BA, Furth SL, Hooper SR.

Pediatr Nephrol. 2020 Mar 10. doi: 10.1007/s00467-020-04511-9. [Epub ahead of print]

PMID:
32157444
3.

Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease.

Oh GJ, Waldo A, Paez-Cruz F, Gipson PE, Pesenson A, Selewski DT, Kamil ES, Massengill SF, Lafayette RA, Modes M, Adler SG, Desmond H, Eikstadt R, Attalla S, Modi ZJ, Troost JP, Gipson DS.

Kidney Int Rep. 2019 Sep 9;4(11):1608-1616. doi: 10.1016/j.ekir.2019.08.019. eCollection 2019 Nov.

4.

Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN).

O'Shaughnessy MM, Troost JP, Bomback AS, Hladunewich MA, Ashoor IF, Gibson KL, Matar RB, Selewski DT, Srivastava T, Rheault MN, Al-Uzri A, Kogon AJ, Khalid M, Vento S, Sanghani NS, Gillespie BW, Gipson DS, Wang CS, Parsa A, Guay-Woodford L, Laurin LP.

Kidney Int Rep. 2019 Sep 16;4(12):1725-1734. doi: 10.1016/j.ekir.2019.09.005. eCollection 2019 Dec.

5.

Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome.

Wang CS, Troost JP, Greenbaum LA, Srivastava T, Reidy K, Gibson K, Trachtman H, Piette JD, Sethna CB, Meyers K, Dell KM, Tran CL, Vento S, Kallem K, Herreshoff E, Hingorani S, Lemley K, Oh G, Brown E, Lin JJ, Kaskel F, Gipson DS.

Kidney Int Rep. 2019 May 7;4(8):1066-1074. doi: 10.1016/j.ekir.2019.04.026. eCollection 2019 Aug.

6.

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators.

N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.

PMID:
31269364
7.

Plasma Zonulin Levels in Childhood Nephrotic Syndrome.

Trachtman H, Gipson DS, Lemley KV, Troost JP, Faul C, Morrison DJ, Vento SM, Ahn DH, Goldberg JD.

Front Pediatr. 2019 May 16;7:197. doi: 10.3389/fped.2019.00197. eCollection 2019.

8.

Using PROMIS® to create clinically meaningful profiles of nephrotic syndrome patients.

Troost JP, Gipson DS, Carlozzi NE, Reeve BB, Nachman PH, Gbadegesin R, Wang J, Modersitzki F, Massengill S, Mahan JD, Liu Y, Trachtman H, Herreshoff EG, DeWalt DA, Selewski DT.

Health Psychol. 2019 May;38(5):410-421. doi: 10.1037/hea0000679.

9.

Health-related quality of life in glomerular disease.

Canetta PA, Troost JP, Mahoney S, Kogon AJ, Carlozzi N, Bartosh SM, Cai Y, Davis TK, Fernandez H, Fornoni A, Gbadegesin RA, Herreshoff E, Mahan JD, Nachman PH, Selewski DT, Sethna CB, Srivastava T, Tuttle KR, Wang CS, Falk RJ, Gharavi AG, Gillespie BW, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Guay-Woodford LM, Reeve B, Gipson DS; CureGN Consortium.

Kidney Int. 2019 May;95(5):1209-1224. doi: 10.1016/j.kint.2018.12.018. Epub 2019 Feb 27.

PMID:
30898342
10.

Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System.

Modi ZJ, Lu Y, Ji N, Kapke A, Selewski DT, Dietrich X, Abbott K, Nallamothu BK, Schaubel DE, Saran R, Gipson DS.

JAMA Cardiol. 2019 Apr 1;4(4):353-362. doi: 10.1001/jamacardio.2019.0375.

11.

Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study.

Hanson CS, Gutman T, Craig JC, Bernays S, Raman G, Zhang Y, James LJ, Ralph AF, Ju A, Manera KE, Teixeira-Pinto A, Viecelli AK, Alexander SI, Blydt-Hansen TD, Dionne J, McTaggart S, Michael M, Walker A, Carter S, Wenderfer SE, Winkelmayer WC, Bockenhauer D, Dart A, Eddy AA, Furth SL, Gipson DS, Goldstein SL, Groothoff J, Samuel S, Sinha A, Webb NJA, Yap HK, Zappitelli M, Currier H, Tong A.

Am J Kidney Dis. 2019 Jul;74(1):82-94. doi: 10.1053/j.ajkd.2018.12.040. Epub 2019 Mar 15.

PMID:
30885704
12.

Soluble ST2 and Galectin-3 and Progression of CKD.

Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, Gadegbeku CA, Gipson DS, Hawkins JJ, Himmelfarb J, Kestenbaum BR, Kretzler M, Robinson-Cohen C, Steigerwalt SP, Tuegel C, Bansal N.

Kidney Int Rep. 2018 Sep 21;4(1):103-111. doi: 10.1016/j.ekir.2018.09.013. eCollection 2019 Jan.

13.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

14.

Consent for Genetic Biobanking in a Diverse Multisite CKD Cohort.

Troost JP, Hawkins J, Jenkins DR, Gipson DS, Kretzler M, El Shamy O, Bellovich K, Perumal K, Bhat Z, Massengill S, Steigerwalt S, Pennathur S, Brosius FC, Gadegbeku CA; Michigan O’Brien Kidney Translational Research Center.

Kidney Int Rep. 2018 Jun 12;3(6):1267-1275. doi: 10.1016/j.ekir.2018.06.002. eCollection 2018 Nov.

15.

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.

Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM; CureGN Consortium.

Am J Kidney Dis. 2019 Feb;73(2):218-229. doi: 10.1053/j.ajkd.2018.07.020. Epub 2018 Nov 9.

16.

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group.

J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091.

17.

Gut Microbial Product Predicts Cardiovascular Risk in Chronic Kidney Disease Patients.

Jadoon A, Mathew AV, Byun J, Gadegbeku CA, Gipson DS, Afshinnia F, Pennathur S; for the Michigan Kidney Translational Core CPROBE Investigator Group.

Am J Nephrol. 2018;48(4):269-277. doi: 10.1159/000493862. Epub 2018 Oct 16.

18.

Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study.

Gutman T, Hanson CS, Bernays S, Craig JC, Sinha A, Dart A, Eddy AA, Gipson DS, Bockenhauer D, Yap HK, Groothoff J, Zappitelli M, Webb NJA, Alexander SI, Goldstein SL, Furth S, Samuel S, Blydt-Hansen T, Dionne J, Michael M, Wenderfer SE, Winkelmayer WC, Currier H, McTaggart S, Walker A, Ralph AF, Ju A, James LJ, Carter S, Tong A.

Am J Kidney Dis. 2018 Oct;72(4):547-559. doi: 10.1053/j.ajkd.2018.05.005. Epub 2018 Jul 3.

19.

Brain abnormalities in children and adolescents with chronic kidney disease.

Matsuda-Abedini M, Fitzpatrick K, Harrell WR, Gipson DS, Hooper SR, Belger A, Poskitt K, Miller SP, Bjornson BH.

Pediatr Res. 2018 Sep;84(3):387-392. doi: 10.1038/s41390-018-0037-5. Epub 2018 Jul 2.

20.

NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome.

Gipson DS, Selewski DT, Massengill SF, Modes MM, Desmond H, Lee L, Kamil E, Elliott MR, Adler SG, Oh G, Lafayette RA, Gipson PE, Sinha A, Bagga A, Pesenson A, Courtlandt C, Spino C, Eikstadt R, Pitter R, Attalla S, Waldo A, Winneker R, Carlozzi NE, Troost JP, Smokler I, Stone M.

Kidney Int Rep. 2017 Nov 28;3(2):439-446. doi: 10.1016/j.ekir.2017.11.016. eCollection 2018 Mar.

21.

Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome.

Trachtman H, Gipson DS, Somers M, Spino C, Adler S, Holzman L, Kopp JB, Sedor J, Overfield S, Elegbe A, Maldonado M, Greka A.

Kidney Int Rep. 2017 Aug 31;3(1):115-121. doi: 10.1016/j.ekir.2017.08.013. eCollection 2018 Jan.

22.

An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.

Troost JP, Trachtman H, Nachman PH, Kretzler M, Spino C, Komers R, Tuller S, Perumal K, Massengill SF, Kamil ES, Oh G, Selewski DT, Gipson P, Gipson DS.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):414-421. doi: 10.2215/CJN.04780517. Epub 2017 Nov 22.

23.

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).

Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, Meyers KE, Pergola P, MacNally ME, Hunt JL, Shih A, Trachtman H.

Kidney Int Rep. 2017 Mar 4;2(4):654-664. doi: 10.1016/j.ekir.2017.02.019. eCollection 2017 Jul.

24.

Assessing responsiveness over time of the PROMIS® pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease.

Reeve BB, Edwards LJ, Jaeger BC, Hinds PS, Dampier C, Gipson DS, Selewski DT, Troost JP, Thissen D, Barry V, Gross HE, DeWalt DA.

Qual Life Res. 2018 Jan;27(1):249-257. doi: 10.1007/s11136-017-1697-z. Epub 2017 Sep 7.

25.

Responsiveness of the PROMIS® measures to changes in disease status among pediatric nephrotic syndrome patients: a Midwest pediatric nephrology consortium study.

Selewski DT, Troost JP, Cummings D, Massengill SF, Gbadegesin RA, Greenbaum LA, Shatat IF, Cai Y, Kapur G, Hebert D, Somers MJ, Trachtman H, Pais P, Seifert ME, Goebel J, Sethna CB, Mahan JD, Gross HE, Herreshoff E, Liu Y, Carlozzi NE, Reeve BB, DeWalt DA, Gipson DS.

Health Qual Life Outcomes. 2017 Aug 23;15(1):166. doi: 10.1186/s12955-017-0737-2.

26.

Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.

Mathias SD, Vallow S, Gipson DS, Thorneloe KS, Sprecher D.

Am J Kidney Dis. 2017 Oct;70(4):532-540. doi: 10.1053/j.ajkd.2017.04.023. Epub 2017 Jun 26.

PMID:
28663063
27.

Improving the evidence for the management of childhood nephrotic syndrome.

Crawford BD, Gipson DS.

Kidney Int. 2017 Jul;92(1):21-23. doi: 10.1016/j.kint.2017.02.029.

PMID:
28646993
28.

Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease.

Chong LSH, Sautenet B, Tong A, Hanson CS, Samuel S, Zappitelli M, Dart A, Furth S, Eddy AA, Groothoff J, Webb NJA, Yap HK, Bockenhauer D, Sinha A, Alexander SI, Goldstein SL, Gipson DS, Raman G, Craig JC.

J Pediatr. 2017 Jul;186:110-117.e11. doi: 10.1016/j.jpeds.2017.03.034. Epub 2017 Apr 24.

PMID:
28449820
29.

Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome.

Beanlands H, Maione M, Poulton C, Herreshoff E, Hladunewich MA, Hailperin M, Modes MM, An L, Nunes JW, Trachtman H, Nachman P, Gipson DS.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i98-i105. doi: 10.1093/ndt/gfw344.

30.

Provider perspectives on treatment decision-making in nephrotic syndrome.

Hladunewich MA, Beanlands H, Herreshoff E, Troost JP, Maione M, Trachtman H, Poulton C, Nachman P, Modes MM, Hailperin M, Pitter R, Gipson DS.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i106-i114. doi: 10.1093/ndt/gfw309.

31.

Development of a Pediatric Adverse Events Terminology.

Gipson DS, Kirkendall ES, Gumbs-Petty B, Quinn T, Steen A, Hicks A, McMahon A, Nicholas S, Zhao-Wong A, Taylor-Zapata P, Turner M, Herreshoff E, Jones C, Davis JM, Haber M, Hirschfeld S.

Pediatrics. 2017 Jan;139(1). pii: e20160985. doi: 10.1542/peds.2016-0985.

32.

A unified framework for evaluating the risk of re-identification of text de-identification tools.

Scaiano M, Middleton G, Arbuckle L, Kolhatkar V, Peyton L, Dowling M, Gipson DS, El Emam K.

J Biomed Inform. 2016 Oct;63:174-183. doi: 10.1016/j.jbi.2016.07.015. Epub 2016 Jul 15.

33.

The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, Lieske JC.

Kidney Int. 2016 Nov;90(5):1080-1089. doi: 10.1016/j.kint.2016.06.020. Epub 2016 Aug 12.

34.

Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease.

Tong A, Samuel S, Zappitelli M, Dart A, Furth S, Eddy A, Groothoff J, Webb NJ, Yap HK, Bockenhauer D, Sinha A, Alexander SI, Goldstein SL, Gipson DS, Hanson CS, Evangelidis N, Crowe S, Harris T, Hemmelgarn BR, Manns B, Gill J, Tugwell P, Van Biesen W, Wheeler DC, Winkelmayer WC, Craig JC; SONG-Kids Investigators.

Trials. 2016 Aug 12;17:401. doi: 10.1186/s13063-016-1528-5.

35.

The Effect of a Gluten-Free Diet in Children With Difficult-to-Manage Nephrotic Syndrome.

Lemley KV, Faul C, Schramm K, Meyers K, Kaskel F, Dell KM, Gipson DS, Gibson K, Trachtman H.

Pediatrics. 2016 Jul;138(1). pii: e20154528. doi: 10.1542/peds.2015-4528.

36.

Patient-Reported Outcomes in Glomerular Disease.

Selewski DT, Thompson A, Kovacs S, Papadopoulos EJ, Carlozzi NE, Trachtman H, Troost JP, Merkel PA, Gipson DS.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):140-148. doi: 10.2215/CJN.13231215. Epub 2016 Jun 3. Review.

37.

Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.

Spino C, Jahnke JS, Selewski DT, Massengill S, Troost J, Gipson DS.

Front Pediatr. 2016 Mar 23;4:25. doi: 10.3389/fped.2016.00025. eCollection 2016.

38.

Hemodialysis outcomes in a global sample of children and young adult hemodialysis patients: the PICCOLO MONDO cohort.

Ferris M, Gibson K, Plattner B, Gipson DS, Kotanko P, Marcelli D, Marelli C, Etter M, Carioni P, von Gersdorff G, Xu X, Kooman JP, Xiao Q, van der Sande FM, Power A, Picoits-Filho R, Sylvestre L, Westreich K, Usvyat L.

Clin Kidney J. 2016 Apr;9(2):295-302. doi: 10.1093/ckj/sfv157. Epub 2016 Mar 5.

39.

Neurocognitive, Social-Behavioral, and Adaptive Functioning in Preschool Children with Mild to Moderate Kidney Disease.

Hooper SR, Gerson AC, Johnson RJ, Mendley SR, Shinnar S, Lande MB, Matheson MB, Gipson DS, Morgenstern B, Warady BA, Furth SL.

J Dev Behav Pediatr. 2016 Apr;37(3):231-8. doi: 10.1097/DBP.0000000000000267.

40.

Fibroblast growth factor-23 and chronic allograft injury in pediatric renal transplant recipients: a Midwest Pediatric Nephrology Consortium study.

Seifert ME, Ashoor IF, Chiang ML, Chishti AS, Dietzen DJ, Gipson DS, Janjua HS, Selewski DT, Hruska KA.

Pediatr Transplant. 2016 May;20(3):378-87. doi: 10.1111/petr.12682. Epub 2016 Feb 15.

41.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

42.

A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS).

Ternant D, Paintaud G, Trachtman H, Gipson DS, Joy MS.

Eur J Clin Pharmacol. 2016 Feb;72(2):253-5. doi: 10.1007/s00228-015-1973-1. Epub 2015 Oct 31. No abstract available.

PMID:
26521258
43.

Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study.

Selewski DT, Chen A, Shatat IF, Pais P, Greenbaum LA, Geier P, Nelson RD, Kiessling SG, Brophy PD, Quiroga A, Seifert ME, Straatmann CE, Mahan JD, Ferris ME, Troost JP, Gipson DS.

Pediatr Nephrol. 2016 Mar;31(3):465-72. doi: 10.1007/s00467-015-3236-x. Epub 2015 Oct 23.

44.

Complement Activation in Patients with Focal Segmental Glomerulosclerosis.

Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H.

PLoS One. 2015 Sep 3;10(9):e0136558. doi: 10.1371/journal.pone.0136558. eCollection 2015.

45.

Matching the Genotype in Resolution: Innovative Ways of Phenotype Capture.

Hicken MT, Gipson DS.

Semin Nephrol. 2015 May;35(3):279-90. doi: 10.1016/j.semnephrol.2015.04.007. Review.

PMID:
26215865
46.

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.

Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS.

BMC Nephrol. 2015 Jul 22;16:111. doi: 10.1186/s12882-015-0094-5.

47.

Optimizing Enrollment of Patients into Nephrology Research Studies.

Selewski DT, Herreshoff EG, Gipson DS.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):512-7. doi: 10.2215/CJN.00500115. Epub 2015 Jul 16.

48.

Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects.

Sampson MG, Robertson CC, Martini S, Mariani LH, Lemley KV, Gillies CE, Otto EA, Kopp JB, Randolph A, Vega-Warner V, Eichinger F, Nair V, Gipson DS, Cattran DC, Johnstone DB, O'Toole JF, Bagnasco SM, Song PX, Barisoni L, Troost JP, Kretzler M, Sedor JR; Nephrotic Syndrome Study Network.

J Am Soc Nephrol. 2016 Mar;27(3):814-23. doi: 10.1681/ASN.2014111131. Epub 2015 Jul 6.

49.

Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method.

Thissen D, Liu Y, Magnus B, Quinn H, Gipson DS, Dampier C, Huang IC, Hinds PS, Selewski DT, Reeve BB, Gross HE, DeWalt DA.

Qual Life Res. 2016 Jan;25(1):13-23. doi: 10.1007/s11136-015-1058-8. Epub 2015 Jun 29.

50.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group.

Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12.

PMID:
26087670

Supplemental Content

Loading ...
Support Center